Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
You may also be interested in...
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.